Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Malignant Melanoma

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 8 articles: HTML format

Single Articles

December 2022
1. SAUD A, Sagineedu SR, Ng HS, Stanslas J, et al
   Melanoma metastasis: What role does melanin play? (Review).
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   July 2022
2. ZHANG YJ, Xie R, Jiang J, Zhai L, et al
   5AzadC suppresses melanoma progression by inhibiting GAS5 hypermethylation.
   Oncol Rep. 2022;48.
   PubMed     Abstract available
   
   
   February 2022
3. KO H, Ahn HJ, Kim YI
   Methylation and mutation of the inhibinalpha gene in human melanoma cells and regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent.
   Oncol Rep. 2022;47.
   PubMed     Abstract available
   
   
   November 2021
4. HAN X, Jia Y, Chen X, Sun C, et al
   lncRNA TINCR attenuates the proliferation and invasion, and enhances the apoptosis of cutaneous malignant melanoma cells by regulating the miR4245p/LATS1 axis.
   Oncol Rep. 2021;46.
   PubMed     Abstract available
   
   
   October 2021
5. CHEN Y, Zhang Z, Luo C, Chen Z, et al
   [Retracted] MicroRNA18b inhibits the growth of malignant melanoma via inhibition of HIF1alphamediated glycolysis.
   Oncol Rep. 2021;46.
   PubMed     Abstract available
   
   
   September 2021
6. KODAMA S, Podyma-Inoue KAlpha, Uchihashi T, Kurioka K, et al
   Progression of melanoma is suppressed by targeting all transforming growth factorbeta isoforms with an Fc chimeric receptor.
   Oncol Rep. 2021;46.
   PubMed     Abstract available
   
   
   August 2021
7. STACHYRA-STRAWA P, Ciesielka M, Janiszewski M, Grzybowska-Szatkowska L, et al
   The role of immunotherapy and moleculartargeted therapy in the treatment of melanoma (Review).
   Oncol Rep. 2021;46.
   PubMed     Abstract available
   
   
   April 2021
8. URANOWSKA K, Kalic T, Valtsanidis V, Kitzwogerer M, et al
   Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.
   Oncol Rep. 2021;45:1.
   PubMed     Abstract available
   
   

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: